Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies

 Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies

Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies

Shots:

  • Synaffix is eligible to receive $246M upfront & milestones along with royalties on net sales. ProfoundBio to get non-exclusive license rights to use Synaffix’s ADC technologies for one therapeutic program to targets specific TAA & also retains license option rights to a second TAA
  • The agreement will access Synaffix’s linker-payload technologies including GlycoConnect & HydraSpace to optimize ADCs therapeutic properties
  • ProfoundBio will be responsible for the research, development, manufacturing & commercialization of ADC products. Synaffix will support ProfoundBio’s research activities & responsible for the manufacturing of components specifically related to its ADC’s technologies

Click here to­ read full press release/ article | Ref: Businesswire | Image: Synaffix

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post